Literature DB >> 17073585

The many antithrombotic actions of nitric oxide.

Constantine Tziros1, Jane E Freedman.   

Abstract

Vessel occlusion within a coronary artery is the precipitating event in unstable coronary syndromes and is primarily due to rupture of atheromatous plaque and subsequent thrombus formation. In the nondiseased vessel, the intact endothelium releases the vasodilator and antithrombotic agent nitric oxide (NO) preventing platelet adherence and activation. In the diseased vessel and during unstable coronary syndromes, release of both endothelial and platelet NO is impaired contributing to thrombus formation. Nitric oxide availability in the vascular system has been associated with various disease states, genetic variants, and medication use. Recently, through the development of new NO donors and by targeting specific signaling pathways, there has been an attempt to enhance the antithrombotic actions of NO as a means to manipulate arterial thrombosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17073585     DOI: 10.2174/138945006778559111

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  11 in total

Review 1.  The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.

Authors:  Michael W Stewart
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

Review 2.  Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology.

Authors:  Gérald Simonneau; Peter Dorfmüller; Christophe Guignabert; Olaf Mercier; Marc Humbert
Journal:  Ann Cardiothorac Surg       Date:  2022-03

3.  SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration.

Authors:  Frank Enseleit; Stephan Michels; Isabella Sudano; Marc Stahel; Sandrine Zweifel; Oliver Schlager; Matthias Becker; Stephan Winnik; Matthias Nägele; Andreas J Flammer; Michel Neidhart; Nicole Graf; Christian M Matter; Burkhardt Seifert; Thomas F Lüscher; Frank Ruschitzka
Journal:  Ophthalmologica       Date:  2017-09-02       Impact factor: 3.250

4.  Ornithine transcarbamylase deficiency: a possible risk factor for thrombosis.

Authors:  Lakshmi Venkateswaran; Fernando Scaglia; Valerie McLin; Paula Hertel; Oleg A Shchelochkov; Saul Karpen; Donald Mahoney; Donald L Yee
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

Review 5.  Endothelial dysfunction: the link between homocysteine and hydrogen sulfide.

Authors:  Sathnur Pushpakumar; Sourav Kundu; Utpal Sen
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

6.  Poly(ethylene glycol) Hydrogel Scaffolds Containing Cell-Adhesive and Protease-Sensitive Peptides Support Microvessel Formation by Endothelial Progenitor Cells.

Authors:  Erica B Peters; Nicolas Christoforou; Kam W Leong; George A Truskey; Jennifer L West
Journal:  Cell Mol Bioeng       Date:  2015-10-20       Impact factor: 2.321

7.  Differential associations of systolic and diastolic time rate of blood pressure variation with carotid atherosclerosis and plaque echogenicity.

Authors:  Athanasios Kolyviras; Efstathios Manios; Georgios Georgiopoulos; Fotios Michas; Thomas Gustavsson; Efthimia Papadopoulou; Laina Ageliki; John Kanakakis; Christos Papamichael; Georgios Stergiou; Nikolaos Zakopoulos; Kimon Stamatelopoulos
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-08-22       Impact factor: 3.738

Review 8.  Impairment of Anti-Aggregatory Responses to Nitric Oxide and Prostacyclin: Mechanisms and Clinical Implications in Cardiovascular Disease.

Authors:  Yuliy Y Chirkov; Thanh H Nguyen; John D Horowitz
Journal:  Int J Mol Sci       Date:  2022-01-18       Impact factor: 5.923

9.  Adiponectin Attenuates Angiotensin II-Induced Vascular Smooth Muscle Cell Remodeling through Nitric Oxide and the RhoA/ROCK Pathway.

Authors:  Wared Nour-Eldine; Crystal M Ghantous; Kazem Zibara; Leila Dib; Hawraa Issaa; Hana A Itani; Nabil El-Zein; Asad Zeidan
Journal:  Front Pharmacol       Date:  2016-04-07       Impact factor: 5.810

10.  Inducible Nitric Oxide Synthase (iNOS) Is a Novel Negative Regulator of Hematopoietic Stem/Progenitor Cell Trafficking.

Authors:  Mateusz Adamiak; Ahmed Abdelbaset-Ismail; Joseph B Moore; J Zhao; Ahmed Abdel-Latif; Marcin Wysoczynski; Mariusz Z Ratajczak
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.